Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract

A technology of tissue factor and inhibitors, applied in the field of airway administration of tissue factor pathway inhibitors in inflammatory conditions affecting the respiratory tract, which can solve the problem of reduced activity of fibrinolysis

Inactive Publication Date: 2008-09-10
DRUGRECURE
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At the same time, local fibrinolysis was significantly inhibited, i.e., coagulation wa

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0132] Localized by bronchoalveolar lavage (BAL) using TFPI Lung Treatment Options

[0133] I. Patient group to be treated

[0134] Respiratory-associated pneumonia, Pneumocystis pneumonia (PCP), or other types of pneumonia secondary to bacterial streptococcal pneumonia despite full antibiotic coverage for the isolated microbial agent or treatment for the associated disease Patients with pneumonia, or ARDS secondary to sepsis, disseminated intravascular coagulation (DIC), trauma, pulmonary aspiration pneumonia, or severe pancreatitis, or bleomycin-induced ARDS being treated with mechanical ventilation, and Patients with ARDS and decreased oxygen capacity (lower oxygen capacity is measured by PaO 2 / FiO 2 The ratio (arterial oxygen tension expressed in mmHg / inspired oxygen fraction) is reduced, ie <200mmHg shows).

[0135] II. Treatment options:

[0136] 5 mg TFPI dissolved in 20 ml saline was administered topically via bronchoalveolar lavage (BAL).

[0137] III. Analy...

Embodiment 2

[0141] Protocols for local pulmonary therapy by inhalation with TFPI

[0142] I. Patient group to be treated:

[0143] Respiratory-associated pneumonia, Pneumocystis pneumonia (PCP), or other types of pneumonia secondary to bacterial streptococcal pneumonia despite full antibiotic coverage for the isolated microbial agent or treatment for the associated disease Patients with pneumonia, or ARDS secondary to sepsis, disseminated intravascular coagulation (DIC), trauma, pulmonary aspiration pneumonia, or severe pancreatitis, or bleomycin-induced ARDS being treated with mechanical ventilation, and Patients with ARDS and decreased oxygen capacity (lower oxygen capacity is measured by PaO 2 / FiO 2 The ratio (arterial oxygen tension in mmHg / inspiratory oxygen fraction) is decreased, ie <200mmHg shows).

[0144] II. Treatment options:

[0145] via sprayer ( ) Topical application of 3 x 5 mg TFPI.

[0146] III. Analysis of results:

[0147] a) By monitoring PaO 2 / FiO 2 The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides methods for the local treatment of acute and chronic extravascular pulmonary fibrin deposition and/or reducing unwanted effects associated with systemic administration of natural anticoagulants to a subject via airway administration to the subject by intratracheal, intrabronchial or intraalveolar routes of natural anticoagulants or biologically active derivatives thereof.

Description

[0001] All patent and non-patent literature cited in the application or in the present application are also incorporated herein by reference in their entirety. field of invention [0002] The present invention provides methods of preventing acute, recurrent and chronic fibrin deposition in the spaces of the airways (particularly alveoli and / or bronchioles) in children and adults in any disease associated with fibrin deposition. These conditions include: inflammatory lung diseases (such as acute lung injury (ALI)), which can be associated with direct or indirect lung trauma, for example, after ventilator therapy (ventilator-induced lung injury (ventilator Induced Lung Injury, VILI)); inflammatory conditions, such as autoimmune diseases, pancreatitis, aspiration pneumonia; inhalation of toxic fumes; acute respiratory distress syndrome (ARDS), which is a more serious manifestation of acute lung injury; infection, Such as sepsis, severe sepsis, and septic shock; pneumonia of any c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/57A61P11/00
CPCA61K9/007A61K9/0075A61K9/0078A61K38/57A61K38/4866A61P1/18A61P11/00A61P11/06A61P11/16A61P29/00A61P31/04A61P43/00A61P7/02A61K38/16A61K38/00
Inventor 拉斯·O·厄滕格尔
Owner DRUGRECURE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap